Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections: a multi-center study [PublishAheadOfPrint]

Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review whereby 60 patients received ceftazidime-avibactam for a CRE infection. In hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.

http://ift.tt/2ptCxsw